- Record: found
- Abstract: found
- Article: not found
Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.
Carsten-O Sahlmann
1 ,
Kia Homayounfar
2 ,
Martin Niessner
2 ,
Jerzy Dyczkowski
3 ,
Lena-Christin Conradi
2 ,
Friederike Braulke
4 ,
Birgit Meller
1 ,
Tim Beißbarth
3 ,
B Michael Ghadimi
2 ,
Johannes Meller
1 ,
David M Goldenberg
5
,
6 ,
Torsten Liersch
2
Feb 15 2017
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) 131 I-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy.